dec-205/ny-eso-1 fusion protein cdx-1401
Biologicalexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00948961)
Timeline
Indications
Studied for
- Anemia, Refractory · Phase 1
- Astrocytoma · Phase 1
- Bone Marrow Cells · Phase 1
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 1
- Hamartoma · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Oligodendroglioma · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Neoplasms · Phase 1
Mechanism of action
- Cancer/testis antigen 1Immunity, active
Cancer/testis antigen 1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cdx-1401
- dec-205/ny-eso-1 fusion protein cdx-1401
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03358719 | Phase 1 | Mar 27, 2018 | Celldex Therapeutics, State University of New York, Buffalo |
| NCT03206047 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02661100 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | Case Western Reserve University, University of Rochester |
| NCT02495636 | Phase 2 | Jul 1, 2015 | Yale University |
| NCT02413827 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Celldex Therapeutics |
| NCT02166905 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2014 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01834248 | Phase 1 | Jul 1, 2013 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01522820 | Phase 1 | Mar 1, 2012 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00948961 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Celldex Therapeutics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| State University of New York, Buffalo | Academic/Hospital | 5 | 4 | 2 | 2012 |
| National Cancer Institute (NCI) | Government | 4 | 1 | 2 | 2012 |
| Celldex Therapeutics | For profit | 3 | 2 | 2 | 2009 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2015 |
6 organizations
Page 1 / 1